首页 > 最新文献

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan最新文献

英文 中文
[Atomic Force Microscopy to Measure the Mechanical Property of Nanosized Lipid Vesicles and Its Applications]. [用原子力显微镜测量纳米脂质囊泡的机械性能及其应用]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00178-2
Yuki Takechi-Haraya

Nanoparticles, including liposomes and lipid nanoparticles, have garnered global attention due to their potential applications in pharmaceuticals, vaccines, and gene therapies. These particles enable targeted delivery of new drug modalities such as highly active small molecules and nucleic acids. However, for widespread use of nanoparticle-based formulations, it is crucial to comprehensively analyze their characteristics to ensure both efficacy and safety, as well as enable consistent production. In this context, this review focuses on our research using atomic force microscopy (AFM) to study liposomes and lipid nanoparticles. Our work significantly contributes to the capability of AFM to measure various types of liposomes in an aqueous medium, providing valuable insights into the mechanical properties of these nanoparticles. We discuss the applications of this AFM technique in assessing the quality of nanoparticle-based pharmaceuticals and developing membrane-active peptides.

纳米粒子(包括脂质体和脂质纳米粒子)因其在制药、疫苗和基因治疗方面的潜在应用而备受全球关注。这些微粒可实现高活性小分子和核酸等新药物的靶向输送。然而,要广泛使用基于纳米粒子的制剂,关键是要全面分析其特性,以确保疗效和安全性,并实现稳定生产。在此背景下,本综述将重点介绍我们利用原子力显微镜(AFM)研究脂质体和脂质纳米粒子的工作。我们的工作大大提高了原子力显微镜测量水介质中各类脂质体的能力,为了解这些纳米颗粒的机械特性提供了宝贵的资料。我们讨论了这种原子力显微镜技术在评估纳米颗粒药物质量和开发膜活性肽方面的应用。
{"title":"[Atomic Force Microscopy to Measure the Mechanical Property of Nanosized Lipid Vesicles and Its Applications].","authors":"Yuki Takechi-Haraya","doi":"10.1248/yakushi.23-00178-2","DOIUrl":"10.1248/yakushi.23-00178-2","url":null,"abstract":"<p><p>Nanoparticles, including liposomes and lipid nanoparticles, have garnered global attention due to their potential applications in pharmaceuticals, vaccines, and gene therapies. These particles enable targeted delivery of new drug modalities such as highly active small molecules and nucleic acids. However, for widespread use of nanoparticle-based formulations, it is crucial to comprehensively analyze their characteristics to ensure both efficacy and safety, as well as enable consistent production. In this context, this review focuses on our research using atomic force microscopy (AFM) to study liposomes and lipid nanoparticles. Our work significantly contributes to the capability of AFM to measure various types of liposomes in an aqueous medium, providing valuable insights into the mechanical properties of these nanoparticles. We discuss the applications of this AFM technique in assessing the quality of nanoparticle-based pharmaceuticals and developing membrane-active peptides.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Life-oriented Chemistry in Pharmaceutical Sciences: Frontiers of Functional Molecule Development for Advanced Molecular Imaging]. [制药科学中以生命为导向的化学:用于先进分子成像的功能分子开发前沿]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00168-F
Yuta Fujikawa, Daisuke Asanuma
{"title":"[Life-oriented Chemistry in Pharmaceutical Sciences: Frontiers of Functional Molecule Development for Advanced Molecular Imaging].","authors":"Yuta Fujikawa, Daisuke Asanuma","doi":"10.1248/yakushi.23-00168-F","DOIUrl":"10.1248/yakushi.23-00168-F","url":null,"abstract":"","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Radiotheranostics Based on Chemical Control of Radioactivity Pharmacokinetics]. [基于放射性药代动力学化学控制的放射治疗]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00168-3
Masahiro Ono

Recently, radiotheranostics, which systematically combines diagnosis by nuclear medicine imaging and treatment by internal radiotherapy, constitutes a new modality in cancer treatment, with some clinical reports showing marked effects on cancer. We have been developing multifunctional chelates containing a target recognition unit, a radiation release unit, and a radioactivity pharmacokinetics control unit in the same molecule to develop efficient agents for cancer radiotheranostics based on chemical control of radioactivity pharmacokinetics. Using these compounds, we have achieved improved cancer accumulation and reduced renal accumulation in tumor-bearing mice, and have developed novel hybrid radiotheranostic agents that can be applied to simultaneously perform target-specific molecular imaging using γ-ray emitting radionuclides and internal radiotherapy using α-particle-emitting radionuclides. For example, 111In/225Ac-labeled PSMA-DA1, which targets prostate-specific membrane antigen (PSMA) for radiotheranostics, achieved clear in vivo imaging of PSMA in tumor-bearing mice and showed marked tumor growth inhibition. In addition to PSMA, this platform for radiotheranostics has also shown efficacy against various cancer target molecules, including carbonic anhydrase IX (CA-IX), which is highly expressed in hypoxic regions of cancer, and glucagon-like peptide-1 receptor (GLP-1R), which is highly expressed in insulinomas. This review presents these recent results of our studies on radiotheranostics for cancer.

近来,将核医学成像诊断和体内放射治疗系统结合起来的放射治疗是癌症治疗的一种新模式,一些临床报告显示其对癌症有明显疗效。我们一直在开发多功能螯合物,在同一分子中包含目标识别单元、辐射释放单元和放射性药代动力学控制单元,以开发基于放射性药代动力学化学控制的癌症放射治疗高效制剂。利用这些化合物,我们改善了肿瘤小鼠的癌症蓄积,减少了肾脏蓄积,并开发出新型混合放射治疗剂,可同时利用γ射线发射放射性核素进行靶点特异性分子成像和利用α粒子发射放射性核素进行内放射治疗。例如,针对前列腺特异性膜抗原(PSMA)进行放射治疗的 111In/225Ac 标记 PSMA-DA1 在肿瘤小鼠体内实现了 PSMA 的清晰成像,并显示出明显的肿瘤生长抑制作用。除 PSMA 外,该放射治疗平台还对多种癌症靶分子具有疗效,包括在癌症缺氧区域高表达的碳酸酐酶 IX(CA-IX)和在胰岛素瘤中高表达的胰高血糖素样肽-1 受体(GLP-1R)。本综述介绍了我们在癌症放射治疗方面的最新研究成果。
{"title":"[Radiotheranostics Based on Chemical Control of Radioactivity Pharmacokinetics].","authors":"Masahiro Ono","doi":"10.1248/yakushi.23-00168-3","DOIUrl":"10.1248/yakushi.23-00168-3","url":null,"abstract":"<p><p>Recently, radiotheranostics, which systematically combines diagnosis by nuclear medicine imaging and treatment by internal radiotherapy, constitutes a new modality in cancer treatment, with some clinical reports showing marked effects on cancer. We have been developing multifunctional chelates containing a target recognition unit, a radiation release unit, and a radioactivity pharmacokinetics control unit in the same molecule to develop efficient agents for cancer radiotheranostics based on chemical control of radioactivity pharmacokinetics. Using these compounds, we have achieved improved cancer accumulation and reduced renal accumulation in tumor-bearing mice, and have developed novel hybrid radiotheranostic agents that can be applied to simultaneously perform target-specific molecular imaging using γ-ray emitting radionuclides and internal radiotherapy using α-particle-emitting radionuclides. For example, <sup>111</sup>In/<sup>225</sup>Ac-labeled PSMA-DA1, which targets prostate-specific membrane antigen (PSMA) for radiotheranostics, achieved clear in vivo imaging of PSMA in tumor-bearing mice and showed marked tumor growth inhibition. In addition to PSMA, this platform for radiotheranostics has also shown efficacy against various cancer target molecules, including carbonic anhydrase IX (CA-IX), which is highly expressed in hypoxic regions of cancer, and glucagon-like peptide-1 receptor (GLP-1R), which is highly expressed in insulinomas. This review presents these recent results of our studies on radiotheranostics for cancer.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Preparation of Nanoplastic Particles as Potential Standards for the Study of Nanoplastics]. [制备纳米塑料粒子作为研究纳米塑料的潜在标准]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00152-1
Kosuke Tanaka, Yusuke Takahashi, Hidetoshi Kuramochi, Masahiro Osako, Go Suzuki

Nanoplastics (NPs) are plastic fragments that are small enough to be absorbed by organisms through ingestion or inhalation. Recent studies indicate that nanoplastics can be ubiquitous in the environment, and there are growing concerns regarding the impacts of nanoplastics on the health of humans and other organisms. However, quantitative information on nanoplastics in the environment is still very limited, and most previous toxicity studies have used only polystyrene (PS) particles because of a lack of appropriate model particles of other plastics. We developed a nanoprecipitation-based method for the preparation of nanoplastic particles of five major polymers: low-density polyethylene (LDPE), high-density polyethylene (HDPE), polypropylene (PP), polyvinyl chloride (PVC), and polystyrene. A major advantage of our method is that the nanoplastic particles are prepared without using reagents that can remain in the particles as impurities. Analysis of the prepared particles' molecular weight (Mw) distributions, crystallinities, and thermal properties revealed that their compositions and constitutions were within the general ranges for commercial products. The mechanisms underlying the formation of low-density polyethylene particles via our method were investigated by means of a simple population balance model, and particle diameter was found to be linearly correlated with the suspension density of the nanoplastic dispersion up to 0.4 mg·mL-1. Future studies should focus on improving our method to allow for precise, scale-independent production of nanoplastic particles. Methods for the preparation of labeled particles are also needed so that such particles can be used in nanoplastic risk assessments.

纳米塑料(NPs)是小到足以被生物体通过摄入或吸入吸收的塑料碎片。最新研究表明,纳米塑料在环境中无处不在,人们越来越关注纳米塑料对人类和其他生物健康的影响。然而,环境中纳米塑料的定量信息仍然非常有限,而且由于缺乏其他塑料的适当模型颗粒,以前的大多数毒性研究都只使用聚苯乙烯(PS)颗粒。我们开发了一种基于纳米沉淀的方法,用于制备五种主要聚合物的纳米塑料粒子:低密度聚乙烯(LDPE)、高密度聚乙烯(HDPE)、聚丙烯(PP)、聚氯乙烯(PVC)和聚苯乙烯。我们的方法的主要优点是制备纳米塑料粒子时无需使用可能作为杂质残留在粒子中的试剂。对所制备颗粒的分子量(Mw)分布、结晶度和热性能进行的分析表明,它们的成分和结构在商业产品的一般范围内。通过一个简单的种群平衡模型,研究了通过我们的方法形成低密度聚乙烯颗粒的机理,发现颗粒直径与纳米塑料分散体的悬浮密度呈线性相关,最高可达 0.4 mg-mL-1。今后的研究应侧重于改进我们的方法,以实现纳米塑料粒子的精确、规模无关的生产。还需要制备标记颗粒的方法,以便在纳米塑料风险评估中使用此类颗粒。
{"title":"[Preparation of Nanoplastic Particles as Potential Standards for the Study of Nanoplastics].","authors":"Kosuke Tanaka, Yusuke Takahashi, Hidetoshi Kuramochi, Masahiro Osako, Go Suzuki","doi":"10.1248/yakushi.23-00152-1","DOIUrl":"10.1248/yakushi.23-00152-1","url":null,"abstract":"<p><p>Nanoplastics (NPs) are plastic fragments that are small enough to be absorbed by organisms through ingestion or inhalation. Recent studies indicate that nanoplastics can be ubiquitous in the environment, and there are growing concerns regarding the impacts of nanoplastics on the health of humans and other organisms. However, quantitative information on nanoplastics in the environment is still very limited, and most previous toxicity studies have used only polystyrene (PS) particles because of a lack of appropriate model particles of other plastics. We developed a nanoprecipitation-based method for the preparation of nanoplastic particles of five major polymers: low-density polyethylene (LDPE), high-density polyethylene (HDPE), polypropylene (PP), polyvinyl chloride (PVC), and polystyrene. A major advantage of our method is that the nanoplastic particles are prepared without using reagents that can remain in the particles as impurities. Analysis of the prepared particles' molecular weight (M<sub>w</sub>) distributions, crystallinities, and thermal properties revealed that their compositions and constitutions were within the general ranges for commercial products. The mechanisms underlying the formation of low-density polyethylene particles via our method were investigated by means of a simple population balance model, and particle diameter was found to be linearly correlated with the suspension density of the nanoplastic dispersion up to 0.4 mg·mL<sup>-1</sup>. Future studies should focus on improving our method to allow for precise, scale-independent production of nanoplastic particles. Methods for the preparation of labeled particles are also needed so that such particles can be used in nanoplastic risk assessments.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Nationwide Survey on Medication Follow-up Care by Community Pharmacists: From The Japanese Nationwide Pharmacy Collaboration Survey in 2023. 关于社区药剂师用药随访护理的全国性调查:2023 年日本全国药房协作调查》。
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/yakushi.24-00016
Shu Sekiya, Rei Tanaka, Hisashi Iijima, Yoshio Nakano, Satoru Miyazaki, Atsushi Toyomi, Hajime Hashiba, Masanori Nagatsu, Yoshiaki Shikamura

In Japan, the Pharmaceutical and Medical Device Act was amended in December 2019, and now requires pharmacists to follow-up on patients during treatment. Although there have been some studies on the effectiveness of follow-ups by pharmacists, there are no reports on the status of implementation in clinical practice. We conducted a nationwide survey on follow-up care to investigate the actual situation. We randomly selected 10% of community pharmacies in each prefecture and conducted a survey. We built a web-based system for the collection of basic information on the pharmacies and follow-up cases. A total of 561 pharmacies were pre-entered. Of these, 110 pharmacies (19.6%) reported 326 follow-up cases. Information was provided to doctors in 129 cases (39.6%), of which prescription proposals were made in 10 (7.8%) instances. The follow-up implementation rate based on the number of prescriptions dispensed was estimated to be 0.84% (95% confidence interval: 0.76-0.94%). This study revealed the status of follow-ups in clinical practice. Pharmacists can contribute to the optimization of drug treatment by providing follow-up information to doctors and making prescription proposals.

日本于 2019 年 12 月修订了《药品和医疗器械法》,现在要求药剂师在治疗期间对患者进行随访。虽然有一些关于药剂师随访效果的研究,但没有关于在临床实践中实施情况的报告。为了解实际情况,我们在全国范围内开展了一次随访护理调查。我们在每个都道府县随机抽取 10%的社区药房进行调查。我们建立了一个网络系统,用于收集药房和随访病例的基本信息。共预先输入了 561 家药房的信息。其中,110 家药房(19.6%)报告了 326 例随访病例。向医生提供信息的有 129 例(39.6%),其中提出处方建议的有 10 例(7.8%)。根据配发处方的数量估算,跟进执行率为 0.84%(95% 置信区间:0.76-0.94%)。这项研究揭示了临床实践中随访的现状。药剂师可通过向医生提供随访信息和提出处方建议,为优化药物治疗做出贡献。
{"title":"A Nationwide Survey on Medication Follow-up Care by Community Pharmacists: From The Japanese Nationwide Pharmacy Collaboration Survey in 2023.","authors":"Shu Sekiya, Rei Tanaka, Hisashi Iijima, Yoshio Nakano, Satoru Miyazaki, Atsushi Toyomi, Hajime Hashiba, Masanori Nagatsu, Yoshiaki Shikamura","doi":"10.1248/yakushi.24-00016","DOIUrl":"https://doi.org/10.1248/yakushi.24-00016","url":null,"abstract":"<p><p>In Japan, the Pharmaceutical and Medical Device Act was amended in December 2019, and now requires pharmacists to follow-up on patients during treatment. Although there have been some studies on the effectiveness of follow-ups by pharmacists, there are no reports on the status of implementation in clinical practice. We conducted a nationwide survey on follow-up care to investigate the actual situation. We randomly selected 10% of community pharmacies in each prefecture and conducted a survey. We built a web-based system for the collection of basic information on the pharmacies and follow-up cases. A total of 561 pharmacies were pre-entered. Of these, 110 pharmacies (19.6%) reported 326 follow-up cases. Information was provided to doctors in 129 cases (39.6%), of which prescription proposals were made in 10 (7.8%) instances. The follow-up implementation rate based on the number of prescriptions dispensed was estimated to be 0.84% (95% confidence interval: 0.76-0.94%). This study revealed the status of follow-ups in clinical practice. Pharmacists can contribute to the optimization of drug treatment by providing follow-up information to doctors and making prescription proposals.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost of Pegfilgrastim for the Prophylaxis of Chemotherapy-induced Febrile Neutropenia in Patients with Breast Cancer Receiving Perioperative Chemotherapy in Daily Practice in Japan: A Posthoc Analysis in a Single-center Retrospective Study. 在日本,Pegfilgrastim 用于预防接受围手术期化疗的乳腺癌患者化疗引起的发热性中性粒细胞减少症的成本:一项单中心回顾性研究的事后分析。
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.1248/yakushi.24-00030
Takuya Tomomatsu, Hisanori Shimizu, Takashi Yokokawa, Ippei Fukada, Kazuyoshi Kawakami, Kazuo Kobayashi, Takeshi Aoyama, Wataru Suzuki, Takahito Sugisaki, Koki Hashimoto, Maimi Asano, Yuka Mori, Fumikata Hara, Toshimi Takano, Shinji Ohno, Masakazu Yamaguchi

This study aimed to estimate the medical costs associated with febrile neutropenia (FN) prophylaxis with pegfilgrastim and evaluate its impact on survival outcomes in daily practice in Japan. In this single-center retrospective study, we obtained data from 296 Japanese patients with breast cancer receiving fluorouracil, epirubicin, and cyclophosphamide (FEC)-100 chemotherapy; the patients were divided into the pegfilgrastim and non-pegfilgrastim groups. We analyzed the median costs of chemotherapy, drugs for all adverse events (AEs) and FN, and hospitalization due to FN. We also assessed the survival outcomes. The pegfilgrastim group showed a significantly higher median total cost (JPY 872320.0 vs. JPY 466715.0, p<0.001). This difference was associated with the prophylactic use of pegfilgrastim. The median costs of the drugs for all AE treatments were JPY 9030.4 and JPY 24690.6, with the non-pegfilgrastim group showing a significantly higher cost (p<0.001). In 11 patients hospitalized for FN management, no significant difference in hospitalization cost was observed between the pegfilgrastim and non-pegfilgrastim groups (JPY 512390.0 vs. JPY 307555.0, p=0.102). No significant difference in the 3-year overall survival was observed between the pegfilgrastim and non-pegfilgrastim groups (79.9% vs. 88.3%, p=0.672). In this study, although the total medical cost in daily practice increased because of primary prophylaxis with pegfilgrastim, the 3-year overall survival was not impacted by the use of pegfilgrastim. Our study data suggested that the primary prophylaxis pegfilgrastim should be used during FEC-100 chemotherapy based on the patient-related FN risk factors, instead of routine use.

本研究旨在估算使用培非格司亭预防发热性中性粒细胞减少症(FN)的相关医疗费用,并评估其在日本日常实践中对生存结果的影响。在这项单中心回顾性研究中,我们获得了接受氟尿嘧啶、表柔比星和环磷酰胺(FEC)-100 化疗的 296 名日本乳腺癌患者的数据;这些患者被分为培吉司汀组和非培吉司汀组。我们分析了化疗、所有不良事件(AEs)和 FN 药物以及因 FN 住院治疗的中位成本。我们还评估了生存结果。pegfilgrastim 组的总费用中位数明显高于非 pegfilgrastim 组(872320.0 日元 vs. 466715.0 日元,p<0.05)。
{"title":"Cost of Pegfilgrastim for the Prophylaxis of Chemotherapy-induced Febrile Neutropenia in Patients with Breast Cancer Receiving Perioperative Chemotherapy in Daily Practice in Japan: A Posthoc Analysis in a Single-center Retrospective Study.","authors":"Takuya Tomomatsu, Hisanori Shimizu, Takashi Yokokawa, Ippei Fukada, Kazuyoshi Kawakami, Kazuo Kobayashi, Takeshi Aoyama, Wataru Suzuki, Takahito Sugisaki, Koki Hashimoto, Maimi Asano, Yuka Mori, Fumikata Hara, Toshimi Takano, Shinji Ohno, Masakazu Yamaguchi","doi":"10.1248/yakushi.24-00030","DOIUrl":"https://doi.org/10.1248/yakushi.24-00030","url":null,"abstract":"<p><p>This study aimed to estimate the medical costs associated with febrile neutropenia (FN) prophylaxis with pegfilgrastim and evaluate its impact on survival outcomes in daily practice in Japan. In this single-center retrospective study, we obtained data from 296 Japanese patients with breast cancer receiving fluorouracil, epirubicin, and cyclophosphamide (FEC)-100 chemotherapy; the patients were divided into the pegfilgrastim and non-pegfilgrastim groups. We analyzed the median costs of chemotherapy, drugs for all adverse events (AEs) and FN, and hospitalization due to FN. We also assessed the survival outcomes. The pegfilgrastim group showed a significantly higher median total cost (JPY 872320.0 vs. JPY 466715.0, p<0.001). This difference was associated with the prophylactic use of pegfilgrastim. The median costs of the drugs for all AE treatments were JPY 9030.4 and JPY 24690.6, with the non-pegfilgrastim group showing a significantly higher cost (p<0.001). In 11 patients hospitalized for FN management, no significant difference in hospitalization cost was observed between the pegfilgrastim and non-pegfilgrastim groups (JPY 512390.0 vs. JPY 307555.0, p=0.102). No significant difference in the 3-year overall survival was observed between the pegfilgrastim and non-pegfilgrastim groups (79.9% vs. 88.3%, p=0.672). In this study, although the total medical cost in daily practice increased because of primary prophylaxis with pegfilgrastim, the 3-year overall survival was not impacted by the use of pegfilgrastim. Our study data suggested that the primary prophylaxis pegfilgrastim should be used during FEC-100 chemotherapy based on the patient-related FN risk factors, instead of routine use.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Evaluation of Pharmacists' Active Intervention to Reduce Potentially Inappropriate Medications in Special Older Adult Nursing Home]. [评估药剂师积极干预以减少特殊老年护理院潜在的不适当药物]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 Epub Date: 2023-10-31 DOI: 10.1248/yakushi.23-00090
Akiko Miki, Hiroki Satoh, Yusaku Matsumoto, Satoko Hori, Yasufumi Sawada

Currently, elderly care facilities that do not offer long-term care are not required to employ pharmacists, and duties such as the dispensing and distribution of medicines are entrusted to external pharmacies. Pharmacists seldom spend sufficient time at the facilities for elderly people requiring special care. Thus, in many cases, the pharmacists have insufficient knowledge of the residents' medication status, leading to their inability in determining whether the residents are receiving a suitable drug therapy. We previously documented various problems in the practices adopted by nursing staff (with negligible intervention by pharmacists) for assisting residents in taking their medications. In the present pilot study, we attempted to eliminate the use of potentially inappropriate medications by stationing a pharmacist at a nursing home for 24 h every week (3 d/week). We proactively collected information from nurses and other nursing staff and observed the residents' actual living conditions and medication use. As a result of this intervention, 56 prescriptions were changed. However, only two of these were changed exclusively based on the prescription information. Most prescriptions were able to change based on the information obtained by the pharmacist present at the facility. Therefore, pharmacists' presence at the facility (at least for a few hours) is necessary, as they can actively intervene and collaborate with other staff to prevent the use of potentially inappropriate medications.

目前,不提供长期护理的养老机构不需要雇佣药剂师,配药和分发药物等职责委托给外部药店。药剂师很少花足够的时间在需要特殊护理的老年人的设施里。因此,在许多情况下,药剂师对居民的药物状况了解不足,导致他们无法确定居民是否正在接受合适的药物治疗。我们之前记录了护理人员在协助住院患者服药时所采取的做法中的各种问题(药剂师的干预可以忽略不计)。在目前的试点研究中,我们试图通过每周在疗养院派驻药剂师24小时(每周三天)来消除潜在的不适当药物的使用。我们积极收集护士和其他护理人员的信息,观察居民的实际生活条件和药物使用情况。由于这种干预,56个处方被更改。然而,其中只有两项仅根据处方信息进行了更改。大多数处方都可以根据该机构药剂师获得的信息进行更改。因此,药剂师在该机构的存在(至少几个小时)是必要的,因为他们可以积极干预并与其他工作人员合作,以防止使用可能不合适的药物。
{"title":"[Evaluation of Pharmacists' Active Intervention to Reduce Potentially Inappropriate Medications in Special Older Adult Nursing Home].","authors":"Akiko Miki, Hiroki Satoh, Yusaku Matsumoto, Satoko Hori, Yasufumi Sawada","doi":"10.1248/yakushi.23-00090","DOIUrl":"10.1248/yakushi.23-00090","url":null,"abstract":"<p><p>Currently, elderly care facilities that do not offer long-term care are not required to employ pharmacists, and duties such as the dispensing and distribution of medicines are entrusted to external pharmacies. Pharmacists seldom spend sufficient time at the facilities for elderly people requiring special care. Thus, in many cases, the pharmacists have insufficient knowledge of the residents' medication status, leading to their inability in determining whether the residents are receiving a suitable drug therapy. We previously documented various problems in the practices adopted by nursing staff (with negligible intervention by pharmacists) for assisting residents in taking their medications. In the present pilot study, we attempted to eliminate the use of potentially inappropriate medications by stationing a pharmacist at a nursing home for 24 h every week (3 d/week). We proactively collected information from nurses and other nursing staff and observed the residents' actual living conditions and medication use. As a result of this intervention, 56 prescriptions were changed. However, only two of these were changed exclusively based on the prescription information. Most prescriptions were able to change based on the information obtained by the pharmacist present at the facility. Therefore, pharmacists' presence at the facility (at least for a few hours) is necessary, as they can actively intervene and collaborate with other staff to prevent the use of potentially inappropriate medications.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71427423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Evaluation of Contractile Function Using Human iPS Cell-derived Cardiomyocytes]. [使用源自人类 iPS 细胞的心肌细胞评估收缩功能]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00164-1
Junko Kurokawa, Satoshi Shimizu, Kazuho Sakamoto

Cardiotoxicity induced by anti-cancer drugs is a significant concern for patients undergoing cancer treatment. Some anti-cancer drugs can damage cardiac muscle cells directly or indirectly, potentially leading to severe heart failure. Various risk factors, including the type and dosage of chemotherapy agents as well as patient background, contribute to the development of cardiotoxicity. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), which enable patient-specific toxicity prediction, hold great promise in this regard. However, the practical implementation of hiPSC-CMs-based prediction of anti-cancer drug-induced cardiotoxicity still faces hurdles. One major challenge involves establishing and optimizing experimental systems for evaluating contractile dysfunction, the ultimate output of heart failure, using hiPSC-CMs. Such efforts are currently underway globally, focusing on tailoring functional evaluation systems to the characteristics of hiPSC-CMs. In this paper, we provide an overview of the contraction mechanisms of cardiac cells and introduce a method of measuring contraction that we have developed, and discuss the current status of contractile function evaluation methods using hiPSC-CMs.

抗癌药物引起的心脏毒性是接受癌症治疗的患者非常关心的问题。一些抗癌药物会直接或间接损害心肌细胞,可能导致严重的心力衰竭。各种风险因素,包括化疗药物的类型和剂量以及患者背景,都会导致心脏毒性的发生。人类诱导多能干细胞衍生心肌细胞(hiPSC-CMs)可预测特定患者的毒性,在这方面大有可为。然而,基于hiPSC-CMs预测抗癌药物诱导的心脏毒性的实际应用仍面临障碍。其中一个主要挑战是建立和优化实验系统,利用 hiPSC-CMs 评估收缩功能障碍(心力衰竭的最终结果)。目前全球都在开展这方面的工作,重点是根据 hiPSC-CMs 的特点定制功能评估系统。本文概述了心脏细胞的收缩机制,介绍了我们开发的一种测量收缩的方法,并讨论了使用 hiPSC-CMs 进行收缩功能评估方法的现状。
{"title":"[Evaluation of Contractile Function Using Human iPS Cell-derived Cardiomyocytes].","authors":"Junko Kurokawa, Satoshi Shimizu, Kazuho Sakamoto","doi":"10.1248/yakushi.23-00164-1","DOIUrl":"10.1248/yakushi.23-00164-1","url":null,"abstract":"<p><p>Cardiotoxicity induced by anti-cancer drugs is a significant concern for patients undergoing cancer treatment. Some anti-cancer drugs can damage cardiac muscle cells directly or indirectly, potentially leading to severe heart failure. Various risk factors, including the type and dosage of chemotherapy agents as well as patient background, contribute to the development of cardiotoxicity. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), which enable patient-specific toxicity prediction, hold great promise in this regard. However, the practical implementation of hiPSC-CMs-based prediction of anti-cancer drug-induced cardiotoxicity still faces hurdles. One major challenge involves establishing and optimizing experimental systems for evaluating contractile dysfunction, the ultimate output of heart failure, using hiPSC-CMs. Such efforts are currently underway globally, focusing on tailoring functional evaluation systems to the characteristics of hiPSC-CMs. In this paper, we provide an overview of the contraction mechanisms of cardiac cells and introduce a method of measuring contraction that we have developed, and discuss the current status of contractile function evaluation methods using hiPSC-CMs.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Route to the Adoption of Quantitative NMR in the Japanese Pharmacopoeia]. [日本药典采用定量核磁共振的途径]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00151-1
Yukihiro Goda

Quantitative NMR (qNMR) is employed to determine the purity of reagents used as standards for HPLC quantification in the Japanese Pharmacopoeia (JP) and has become recognized as a new absolute quantification method in various fields such as pharmaceuticals, foods, and food additives. This report outlines how and why qNMR has been adopted as an official method in the JP and introduces its progression from JP16 to JP18. The results of a survey of companies in the Japan Pharmaceutical Manufacturers' Association regarding how and when to use qNMR from development to manufacturing stages are introduced. The issues involved in the expansion of the use of qNMR in the field of chemical pharmaceuticals in 2017 are discussed and how these were resolved.

定量核磁共振(qNMR)被用于测定《日本药典》(JP)中用作高效液相色谱定量标准的试剂的纯度,并已成为药品、食品和食品添加剂等各个领域公认的新的绝对定量方法。本报告概述了 qNMR 成为日本药典正式方法的过程和原因,并介绍了它从 JP16 到 JP18 的发展历程。报告还介绍了日本制药商协会就从开发到生产阶段如何以及何时使用 qNMR 对各公司进行调查的结果。讨论了 2017 年在化学制药领域扩大使用 qNMR 所涉及的问题以及如何解决这些问题。
{"title":"[Route to the Adoption of Quantitative NMR in the Japanese Pharmacopoeia].","authors":"Yukihiro Goda","doi":"10.1248/yakushi.23-00151-1","DOIUrl":"10.1248/yakushi.23-00151-1","url":null,"abstract":"<p><p>Quantitative NMR (qNMR) is employed to determine the purity of reagents used as standards for HPLC quantification in the Japanese Pharmacopoeia (JP) and has become recognized as a new absolute quantification method in various fields such as pharmaceuticals, foods, and food additives. This report outlines how and why qNMR has been adopted as an official method in the JP and introduces its progression from JP16 to JP18. The results of a survey of companies in the Japan Pharmaceutical Manufacturers' Association regarding how and when to use qNMR from development to manufacturing stages are introduced. The issues involved in the expansion of the use of qNMR in the field of chemical pharmaceuticals in 2017 are discussed and how these were resolved.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140332025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Metabolic Activities Catalyzed by Human Cytochrome P450 (CYP) 2D6 and CYP3A Subfamily Members and Effect of Various Compounds, Including Endogenous Steroid Hormones, on These Activities]. [人类细胞色素 P450 (CYP) 2D6 和 CYP3A 亚家族成员催化的代谢活性以及各种化合物(包括内源性类固醇激素)对这些活性的影响]。
IF 0.3 4区 医学 Q4 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00174
Toshiro Niwa

My research focused on the effects of various drugs on (1) dopamine formation from p-tyramine catalyzed by polymorphic cytochrome P450 (CYP or P450) 2D6 variants and (2) endogenous steroid hormone hydroxylation catalyzed by CYP3A subfamily members (CYP3A4, CYP3A5, CYP3A7). The activation (cooperativity) of metabolic reactions catalyzed by P450s was especially emphasized. The effects of various psychotropic agents on dopamine formation from p-tyramine, catalyzed by wild-type CYP2D6.1 and CYP2D6 variants, including CYP2D6.2 (Arg296Cys;Ser486Thr), CYP2D6.10 (Pro34Ser;Ser486Thr), and CYP2D6.39 (Ser486Thr) were compared. Michaelis (Km) and inhibition (Ki) constants of the psychotropic agents in the presence of CYP2D6.10 were higher than those observed in the presence of other CYP2D6 variants. Fluvoxamine, fluoxetine, milnacipran, and haloperidol activated CYP2D6-catalyzed dopamine formation [decreasing the Km and/or increasing the maximal velocity (kcat)], and this activation was CYP2D6 variant-dependent. Regarding the CYP3A subfamily, the effects of various compounds including endogenous steroid hormones on the 6β-hydroxylation of steroid hormones, such as testosterone, progesterone, and cortisol, were determined; it was found that testosterone, dehydroepiandrosterone, and/or α-naphthoflavone activated 6β-hydroxylation of cortisol and/or progesterone, but the effects varied in the presence of different CYP3A subfamily members. Further studies are required to confirm the mechanisms and therapeutic relevance of these activation phenomena.

我的研究重点是各种药物对以下方面的影响:(1) 多态细胞色素 P450(CYP 或 P450)2D6 变体催化的对酪胺多巴胺形成;(2) CYP3A 亚家族成员(CYP3A4、CYP3A5、CYP3A7)催化的内源性类固醇激素羟化。特别强调了 P450s 催化的代谢反应的活化(合作性)。在野生型 CYP2D6.1 和 CYP2D6 变体(包括 CYP2D6.2(Arg296Cys;Ser486Thr)、CYP2D6.10(Pro34Ser;Ser486Thr)和 CYP2D6.39(Ser486Thr))的催化下,比较了各种精神药物对对酪胺形成多巴胺的影响。在 CYP2D6.10 存在的情况下,精神药物的迈克尔斯常数(Km)和抑制常数(Ki)高于在其他 CYP2D6 变体存在的情况下观察到的数值。氟伏沙明、氟西汀、米那西普兰和氟哌啶醇能激活 CYP2D6 催化的多巴胺形成[降低 Km 和/或增加最大速度(kcat)],这种激活作用与 CYP2D6 变体有关。关于 CYP3A 亚家族,研究人员测定了各种化合物(包括内源性类固醇激素)对类固醇激素(如睾酮、孕酮和皮质醇)的 6β- 羟基化的影响;结果发现,睾酮、脱氢表雄酮和/或 α-萘甲黄酮可激活皮质醇和/或孕酮的 6β- 羟基化,但在不同的 CYP3A 亚家族成员存在的情况下,其影响有所不同。要确认这些激活现象的机制和治疗相关性,还需要进一步的研究。
{"title":"[Metabolic Activities Catalyzed by Human Cytochrome P450 (CYP) 2D6 and CYP3A Subfamily Members and Effect of Various Compounds, Including Endogenous Steroid Hormones, on These Activities].","authors":"Toshiro Niwa","doi":"10.1248/yakushi.23-00174","DOIUrl":"10.1248/yakushi.23-00174","url":null,"abstract":"<p><p>My research focused on the effects of various drugs on (1) dopamine formation from p-tyramine catalyzed by polymorphic cytochrome P450 (CYP or P450) 2D6 variants and (2) endogenous steroid hormone hydroxylation catalyzed by CYP3A subfamily members (CYP3A4, CYP3A5, CYP3A7). The activation (cooperativity) of metabolic reactions catalyzed by P450s was especially emphasized. The effects of various psychotropic agents on dopamine formation from p-tyramine, catalyzed by wild-type CYP2D6.1 and CYP2D6 variants, including CYP2D6.2 (Arg296Cys;Ser486Thr), CYP2D6.10 (Pro34Ser;Ser486Thr), and CYP2D6.39 (Ser486Thr) were compared. Michaelis (K<sub>m</sub>) and inhibition (K<sub>i</sub>) constants of the psychotropic agents in the presence of CYP2D6.10 were higher than those observed in the presence of other CYP2D6 variants. Fluvoxamine, fluoxetine, milnacipran, and haloperidol activated CYP2D6-catalyzed dopamine formation [decreasing the K<sub>m</sub> and/or increasing the maximal velocity (k<sub>cat</sub>)], and this activation was CYP2D6 variant-dependent. Regarding the CYP3A subfamily, the effects of various compounds including endogenous steroid hormones on the 6β-hydroxylation of steroid hormones, such as testosterone, progesterone, and cortisol, were determined; it was found that testosterone, dehydroepiandrosterone, and/or α-naphthoflavone activated 6β-hydroxylation of cortisol and/or progesterone, but the effects varied in the presence of different CYP3A subfamily members. Further studies are required to confirm the mechanisms and therapeutic relevance of these activation phenomena.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139698431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1